Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $59.60 Consensus Price Target from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $59.60.

A number of equities research analysts have issued reports on JANX shares. BTIG Research started coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price target on the stock. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Wedbush reissued an “outperform” rating and issued a $53.00 price target on shares of Janux Therapeutics in a report on Monday, March 11th. Bank of America raised their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th. Finally, Cantor Fitzgerald started coverage on shares of Janux Therapeutics in a report on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 price target on the stock.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of JANX. JPMorgan Chase & Co. lifted its position in shares of Janux Therapeutics by 34.9% in the 1st quarter. JPMorgan Chase & Co. now owns 17,926 shares of the company’s stock worth $256,000 after purchasing an additional 4,638 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Janux Therapeutics by 25.9% in the 1st quarter. Bank of New York Mellon Corp now owns 46,001 shares of the company’s stock worth $660,000 after purchasing an additional 9,464 shares during the period. MetLife Investment Management LLC lifted its position in shares of Janux Therapeutics by 100.2% in the 1st quarter. MetLife Investment Management LLC now owns 10,614 shares of the company’s stock worth $152,000 after purchasing an additional 5,312 shares during the period. Rhumbline Advisers lifted its position in shares of Janux Therapeutics by 46.9% in the 1st quarter. Rhumbline Advisers now owns 16,216 shares of the company’s stock worth $233,000 after purchasing an additional 5,179 shares during the period. Finally, BlackRock Inc. lifted its position in shares of Janux Therapeutics by 15.2% in the 1st quarter. BlackRock Inc. now owns 1,161,721 shares of the company’s stock worth $16,659,000 after purchasing an additional 153,460 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

JANX stock opened at $37.92 on Thursday. Janux Therapeutics has a 52 week low of $5.65 and a 52 week high of $58.69. The firm’s fifty day moving average is $23.71 and its 200 day moving average is $14.23. The firm has a market cap of $1.96 billion, a P/E ratio of -28.30 and a beta of 4.31.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.